title: APOE ε4 influences β-amyloid deposition in primary progressive aphasia and speech apraxia.
abstract: BACKGROUND
  Apolipoprotein E ε4 (APOE ε4) is a risk factor for β-amyloid deposition in Alzheimer's disease dementia. Its influence on β-amyloid deposition in speech and language disorders, including primary progressive aphasia (PPA), is unclear.
  
  
  METHODS
  One hundred thirty subjects with PPA or progressive speech apraxia underwent APOE genotyping and Pittsburgh compound B (PiB) PET scanning. The relationship between APOE ε4 and PiB status, as well as severity and regional distribution of PiB, was assessed.
  
  
  RESULTS
  Forty-five subjects had an APOE ε4 allele and 60 subjects were PiB-positive. The odds ratio for a subject with APOE ε4 being PiB-positive compared with a subject without APOE ε4 being PiB-positive was 10.2 (95% confidence interval, 4.4-25.5; P < .0001). The APOE ε4 allele did not influence regional PiB distribution or severity.
  
  
  CONCLUSIONS
  APOE ε4 increases the risk of β-amyloid deposition in PPA and progressive speech apraxia but does not influence regional β-amyloid distribution or severity.
authors.affiliation: Division of Behavioral Neurology, Department of Neurology, Mayo Clinic, Rochester, MN, USA; Division of Movement Disorders, Department of Neurology, Mayo Clinic, Rochester, MN, USA. Electronic address: Josephs.keith@mayo.edu.
authors.forename: Keith A
authors.initials: KA
authors.lastname: Josephs
authors.affiliation: Division of Speech Pathology, Department of Neurology, Mayo Clinic, Rochester, MN, USA.
authors.forename: Joseph R
authors.initials: JR
authors.lastname: Duffy
authors.affiliation: Division of Speech Pathology, Department of Neurology, Mayo Clinic, Rochester, MN, USA.
authors.forename: Edythe A
authors.initials: EA
authors.lastname: Strand
authors.affiliation: Division of Neuropsychology, Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.
authors.forename: Mary M
authors.initials: MM
authors.lastname: Machulda
authors.affiliation: Department of Information Technology, Mayo Clinic, Rochester, MN, USA.
authors.forename: Matthew L
authors.initials: ML
authors.lastname: Senjem
authors.affiliation: Division of Nuclear Medicine, Department of Radiology, Mayo Clinic, Rochester, MN, USA.
authors.forename: Val J
authors.initials: VJ
authors.lastname: Lowe
authors.affiliation: Division of Neuroradiology, Department of Radiology, Mayo Clinic, Rochester, MN, USA.
authors.forename: Clifford R
authors.initials: CR
authors.lastname: Jack
authors.affiliation: Division of Neuroradiology, Department of Radiology, Mayo Clinic, Rochester, MN, USA.
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Whitwell
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D016229:Amyloid beta-Peptides / Q000378:metabolism*; D000814:Aniline Compounds; D018888:Aphasia, Primary Progressive / Q000000981:diagnostic imaging* / Q000235:genetics*; D053327:Apolipoprotein E4 / Q000235:genetics*; D001072:Apraxias / Q000000981:diagnostic imaging* / Q000235:genetics*; D001931:Brain Mapping; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D013844:Thiazoles
chemical_list: C475519:2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole; D016229:Amyloid beta-Peptides; D000814:Aniline Compounds; D053327:Apolipoprotein E4; D013844:Thiazoles
keywords: Apolipoprotein; Logopenic aphasia; Pittsburgh compound B; Primary progressive aphasia; Speech apraxia